| Added by | pmartino |
|---|---|
| Group name | EquipePM |
| Item Type | Journal Article |
| Title | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study |
| Creator | Trecourt et al. |
| Author | Alexis Trecourt |
| Author | Naoual Bakrin |
| Author | Olivier Glehen |
| Author | Witold Gertych |
| Author | Laurent Villeneuve |
| Author | Sylvie Isaac |
| Author | Nazim Benzerdjeb |
| Author | Juliette Fontaine |
| Author | Catherine Genestie |
| Author | Peggy Dartigues |
| Author | Agnès Leroux |
| Author | Cecile Odin |
| Author | Lakhdar Khellaf |
| Author | Magali Svrcek |
| Author | Sixte Thierry |
| Author | Marilyn Augros |
| Author | Alhadeedi Omar |
| Author | Mojgan Devouassoux-Shisheboran |
| Author | Vahan Kepenekian |
| Abstract | BACKGROUND: Ovarian pseudomyxoma peritonei (OPMP) are rare, without well-defined therapeutic guidelines. We aimed to evaluate cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat OPMP. METHODS: Patients from the French National Network for Rare Peritoneal Tumors (RENAPE) database with proven OPMP treated by CRS/HIPEC and with histologically normal appendix and digestive endoscopy were retrospectively included. Clinical and follow-up data were collected. Histopathological and immunohistochemical features were reviewed. RESULTS: Fifteen patients with a median age of 56 years were included. The median Peritoneal Cancer Index was 16. Following CRS, the completeness of cytoreduction (CC) score was CC-0 for 9/15 (60%) patients, CC-1 for 5/15 (33.3%) patients, and CC-2 for 1/15 (6.7%) patients. The median tumor size was 22.5 cm. After pathological review and immunohistochemical studies, tumors were classified as Group 1 (mucinous ovarian epithelial neoplasms) in 3/15 (20%) patients; Group 2 (mucinous neoplasm in ovarian teratoma) in 4/15 (26.7%) patients; Group 3 (mucinous neoplasm probably arising in ovarian teratoma) in 5/15 (33.3%) patients; and Group 4 (non-specific group) in 3/15 (20%) patients. Peritoneal lesions were OPMP pM1a/acellular, pM1b/grade 1 (hypocellular) and pM1b/grade 3 (signet-ring cells) in 13/15 (86.7%), 1/15 (6.7%) and 1/15 (6.7%) patients, respectively. Disease-free survival analysis showed a difference (p = 0.0463) between OPMP with teratoma/likely-teratoma origin (groups 2 and 3; 100% at 1, 5, and 10 years), and other groups (groups 1 and 4; 100%, 66.6%, and 50% at 1, 5, and 10 years, respectively). CONCLUSION: These results suggested that a primary therapeutic strategy using complete CRS/HIPEC for patients with OPMP led to favorable long-term outcomes. |
| Publication | Annals of Surgical Oncology |
| Volume | 31 |
| Issue | 5 |
| Pages | 3325-3338 |
| Date | 2024-05 |
| Journal Abbr | Ann Surg Oncol |
| Language | eng |
| DOI | 10.1245/s10434-023-14850-0 |
| ISSN | 1534-4681 |
| Short Title | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin |
| Library Catalog | PubMed |
| Extra | PMID: 38341381 PMCID: PMC10997733 |
| Tags | Appendiceal Neoplasms, clinic, Combined Modality Therapy, Cytoreduction, Cytoreduction Surgical Procedures, Female, HIPEC, Humans, Hyperthermia, Induced, Middle Aged, Mucinous tumor from teratoma, Neoplasms, Cystic, Mucinous, and Serous, Ovarian pseudomyxoma, Peritoneal pseudomyxoma, Retrospective Studies, Survival Rate, Teratoma |
| Date Added | 2024/08/02 - 09:54:27 |
| Date Modified | 2024/08/02 - 10:00:39 |
| Notes and Attachments | Full Text (Attachment) PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
